about

Dr. Rosen is a Professor in the Departments of Chemical Physiology & Immunology at The Scripps Research Institute in La Jolla, California where he focuses on pursuing his primary interests in lymphocyte trafficking and barrier regulation by signaling lipids, and contributing towards the development of translational infrastructure at TSRI. He chairs the Molecular Libraries Screening Network Steering Group, a part of the NIH Roadmap, and is PI of the Scripps Research Institute Molecular Screening Center, which recently was awarded an $88M grant from the National Institutes of Health. For more than a decade he served in various capacities at Merck Research Laboratories including Executive Director and Therapeutic Area head, and chair of Merck's Anti-bacterial and anti-fungal Worldwide Business Strategy Team. Since 2002 he has been a professor at the Scripps Research Institute, He is Associate Editor of Molecular Pharmacology and on the Editorial board of Journal of Biological Chemistry. Dr Rosen is active in supporting medical research charities, having served on the Scientific Board of the Scleroderma Foundation from1992-2000, and currently serves on the Scientific Board of the Myeloproliferative Diseases Foundation. He was elected to the Association of American Physicians in 2008. He received his MB.ChB. (M.D.) with distinction and honors from the University of Cape Town. He attended the University of Oxford as a Royal Commission for the Exhibition of 1851 Scholar, and received his D.Phil. in Physiological Sciences at the Sir William Dunn School of Pathology. He remained in Oxford as a Junior Research Fellow at Jesus College, also receiving a Wellcome Senior Fellowship.

Dr. Stevens is a Professor in the Departments of Molecular Biology and Chemistry at The Scripps Research Institute in La Jolla, California where he is focused on both the basic and applied areas of structural biology. Prior to moving to Scripps in 1999, Dr. Stevens was a Professor of Chemistry and Neurobiology at the University of California, Berkeley. He has helped to pioneer the area of high throughput structural biology, founding multiple biotechnology companies including Syrrx (now Takeda San Diego), as well as establishing several National Institutes of Health supported structural biology research centers. Dr. Stevens has published more than 240 peer reviewed publications in the past 20 years, focusing primarily in the area of structural biology and structure based drug discovery including involvement in the development of Tamiflu™, Kuvan™, PEG-PAL™, and Alogliptin™. He obtained his B.S. in Chemistry at the University of Southern Maine, his Ph.D. in Chemistry at the University of Southern California, and conducted his post-doctoral research in structural biology in the Chemistry Department at Harvard University.